Zacks Rank on Proteon Therapeutics, Inc. (PRTO) based on Estimated Earnings

Proteon Therapeutics, Inc. (NASDAQ:PRTO) is a hold, according to the latest average broker rating of 2.5. The number of analysts in this rating is 8. Research Analysts at Zacks has the stock a rating of 3, which implies that the firms recommendation is Neutral on the company. Proteon Therapeutics, Inc. (NASDAQ:PRTO): 5 Analyst have given the stock of Proteon Therapeutics, Inc. (NASDAQ:PRTO) a near short term price target of $10.2. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $8.64. The higher price target estimate is at $21 while the lower price estimates are fixed at $3.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) : On Thursday heightened volatility was witnessed in Proteon Therapeutics, Inc. (NASDAQ:PRTO) which led to swings in the share price. The stock opened for trading at $1.75 and hit $2.15 on the upside , eventually ending the session at $1.75, with a gain of 2.94% or 0.05 points. The heightened volatility saw the trading volume jump to 934,643 shares. The 52-week high of the share price is $11.63 and the company has a market cap of $29 million. The 52-week low of the share price is at $1.4 .

Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass.

Proteon

Leave a Reply

Your email address will not be published. Required fields are marked *